CytomX Therapeutics (CTMX) Deferred Taxes (2015 - 2017)

CytomX Therapeutics (CTMX) posted Deferred Taxes of -$520000.0 for Q4 2017, down 2636.84% on a QoQ basis from -$19000.0 in Q3 2017.

CytomX Therapeutics (CTMX) Deferred Taxes (2015 - 2017) Analysis & Trends

CytomX Therapeutics' Deferred Taxes history runs 3 years deep, the most recent figure standing at -$520000.0 for Q4 2017.

Quarterly Deferred Taxes changed N/A year-over-year to -$520000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was -$513000.0 (down 8650.0% YoY) and the FY2017 annual result came in at -$513000.0, down 8650.0% from the prior year.
Deferred Taxes was -$520000.0 for Q4 2017 at CytomX Therapeutics, down from -$19000.0 in the prior quarter.
Across five years, Deferred Taxes topped out at $25000.0 in Q2 2017 and bottomed at -$520000.0 in Q4 2017.
A 3-year average of -$72000.0 and a median of $3000.0 in 2015 frame the typical range for Deferred Taxes.
Peak annual rise in Deferred Taxes reached 733.33% in 2017, while the deepest fall reached 66.67% in 2017.
CytomX Therapeutics' Deferred Taxes stood at $3000.0 in 2015, then changed by 0.0% to $3000.0 in 2016, then plunged by 17433.33% to -$520000.0 in 2017.
Business Quant data shows CTMX's Deferred Taxes at -$520000.0 in Q4 2017, -$19000.0 in Q3 2017, and $25000.0 in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-188,883.60
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-65.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	96.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytomX Therapeutics	590.32 Mn	243.61 Mn	-	-

Download Data